Association of growth factors, HIF-1 and NF-κB expression with proteasomes in endometrial cancer

Molecular Biology Reports

Volumn 39, Issue 9, 2012, Pages 8655-8662

  Spirina, Ludmila V ^a   Yunusova, Nataliya V ^a   Kondakova, Irina V ^a   Kolomiets, Larisa A ^a   Koval, Valeriya D ^a   Chernyshova, Alena L ^a   Shpileva, Olga V ^a  

^a CANCER RESEARCH INSTITUTE   (Russian Federation)

Author keywords

Endometrial cancer; Hypoxia inducible factor 1; Insulin like growth factors; Nuclear factor kappa B; Proteasome; Vascular endothelial growth factor

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEASOME; PROTEIN P50; SOMATOMEDIN C; TRANSCRIPTION FACTOR; VASCULOTROPIN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CANCER; FEMALE; HUMAN; HUMAN TISSUE; MUTATION; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS;

ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865116493     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-1720-y     Document Type: Article

References (41)

1. Holman L, Lu K (2012) The epidemiology of endometrial cancer. Glob libr women's med (ISSN: 1756-2228). doi: 10.3843/GLOWM.10236
2. Berstein LM, Tchernobrovkina AE, Gamayunova VB, Kovalevskij AJ, Vasilyev DA, Chepik OF, Turkevitch EA, Tsyrlina EV, Maximov SJ, Ashrafian LA, Thijssen JH (2003) Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J Cancer Res Clin Oncol 129(4):245-249 (Pubitemid 36713801)
3. Firth SM (2002) Baxter RC Cellular action of the insulin-like growth factor binding proteins. Endocr Rev 23:824-854 (Pubitemid 35454590)
4. Zhang H, Yee D (2006) Is the type I insulin-like growth factor receptor a therapeutic target in endometrial cancer? Clin Cancer Res 12:6323-6325 (Pubitemid 44799699)
5. McCampbell AS, Broaddus RR, Loose DS, Davis PJA (2006) Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clin Cancer Res 12:6373-6378 (Pubitemid 44799707)
6. Badinga L, Song S, Simmen RCM, Clarke JB, Clemmons DR, Simmen FA (1999) Complex mediation of uterine endometrial epithelial cell growth by insulin-like growth factor-II (IGF-II) and IGF-binding protein-2. J Mol Endocrinol 23:277-285 (Pubitemid 30055984)
7. Gielen SC (2005) Steroid-modulated proliferation of human endometrial carcinoma cell lines: any role for insulin-like growth factor signaling? J Soc Gynecol Investig 12:58-64 (Pubitemid 40039067)
8. Molitoris KH, Kazi AA, Koos RD (2009) Inhibition of oxygen-induced hypoxia-inducible factor-1 alpha degradation unmasks estradiol induction of vascular endothelial growth factor expression in ECC-1 cancer cells in vitro. Endocrinology 150(12):5405-5414
9. Dobrzycka B, Terlikowski SJ, Kwiatkowski M, Garbowicz M, Kinalski M, Chyczewski L (2010) Prognostic significance of VEGF and its receptors in endometrioid endometrial cancer. Ginekol Pol 81:422-425
10. Feldser D, Agani F, Iyer NV et al (1999) Reciprocal positive regulation of hypoxia-inducible factor 1 alpha and insulin-like growth factor 2. Cancer Res 59(16):3915-3918 (Pubitemid 29393552)
11. Beppu K, Nakamura K, Linehan WM et al (2005) Topotecan blocks hypoxia-inducible factor-1 alpha and vascular endothelial growth expression induced by insulin-like growth factor-1 in neuroblastoma cells. Cancer Res 65(11):4775-4781 (Pubitemid 40740815)
12. Gariboldi MB, Ravizza R, Monti E (2010) The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and proangiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells. Biochem Pharmacol 80(4):455-462
13. Seeber LM, Zweemer RP, Verheijen RH et al (2010) Hypoxia-inducible factor-1 as a therapeutic target in endometrial cancer management. Obstet Gynecol Int 2010:580971-580979
14. Zhou J, Kohl R, Herr B et al (2006) Calpain mediates a von Hippel-Lindau protein-independent destruction of hypoxia-inducible factor-1α. Mol Biol Cell 17(4):1549-1558 (Pubitemid 44011575)
15. Baldwin AS (1996) The NF-kappa B and I-kappa B proteins: new discoveries and insights. Annu Rev Immunol 14:649-683 (Pubitemid 26130197)
16. Goldberg AL (2007) Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 35:12-17
17. Kostadinova RM, Nawrocki AR, Frey FJ, Frey BM (2005) Tumor necrosis factor alpha and phorbol 12-myristate-13-acetate down-regulate human 11 beta-hydroxysteroid dehydrogenase type 2 through p50/p50 NF-kappaB homodimers and Egr-1. FASEB J 19(6):650-652 (Pubitemid 40471274)
18. Marui N, Medford RM, Ahmad M (2005) Activation of RelA homodimers by tumor necrosis factor alpha: a possible transcriptional activator in human vascular endothelial cells. Biochem J 390:317-324 (Pubitemid 41192258)
19. Juvekar A, Manna S, Ramaswami S, Chang TP, Vu HY, Ghosh CC, Celiker MY, Vancurova I (2011) Bortezomib induces nuclear translocation of IkBα resulting in gene-specific suppression of NF-kB-dependent transcription and induction of apoptosis in CTCL. Mol Cancer Res 9(2):183-194
20. Conner JR, Smirnova II, Moseman AP, Poltorak A (2010) IRAK1BP1 inhibits inflammation by promoting nuclear translocation of NF-kappaB p50. Proc Natl Acad Sci USA 107(25):11477-11482
21. Almond JB, Cohen GM (2002) The proteasome: a novel target for cancer chemotherapy. Leukemia 16(4):433-443 (Pubitemid 34449723)
22. Fan M, Narshatri H, Nephew KP (2004) Inhibiting proteasomal proteolysis sustains estrogen receptor-alpha activation. Mol Endocrinol 18(11):2603-2615 (Pubitemid 39482052)
23. Satoh S, Yanagita T, Maruta T et al (2008) Proteasomal degradation of IRS-2, but not IRS-1 by calcineurin inhibition: attenuation of insulin-like growth factor-I-induced GSK-3 beta and ERK pathways in adrenal chromaffin cells. Neuropharmacology 55(1):71-79
24. Girnita L, Girnita A, Larsson O (2003) Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc Nat Acad Sci USA 100:8247-8252 (Pubitemid 36842530)
25. Yue CX, Ma J, Zhou HJ et al (2011) The effect of RhoA and proteasome inhibitor MG132 on angiogenesis in tumors. Sichuan Da Xue Xue Bao Yi Xue Ban 42(4):445-451
26. Muller M, Morotti A, Ponzetto C (2002) Activation of NF-B is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol 22(4):13012-13017 (Pubitemid 34094843)
27. Cramer M, Nagy I, Murphy BJ, Gassmann M, Hottiger MO, Georgiev O, Schaffner W (2005) NF-kappaB contributes to transcription of placenta growth factor and interacts with metal responsive transcription factor-1 in hypoxic human cells. Biol Chem 386(9):865-872 (Pubitemid 41448142)
28. Crisostomo PR, Wang Y, Markel T et al (2008) Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by NF kappa B- but not JNK-dependent mechanism. Am Physiol Cell Physiol 294(3):675-682 (Pubitemid 351468685)
29. Kondakova IV, Spirina LV, Shashova EE, Koval VD, Kolomiets LA, Chernyshova AL, Slonimskaya EM (2012) Proteasome activity in tumors of the female reproductive system. Russ J Bioorg Chem 38:89-92
30. Abramova EB, Astakhova TM, Erokhov PA, Sharova NP (2004) Multiple forms of the proteasomes and some approaches to their separation. Izv Akad Nauk Ser Biol 2:150-156
31. Ben-Shahar S, Komlosh A, Nadav E, Shaked I, Ziv T, Admon A, DeMartino GN, Reiss Y (1999) 26S proteasome-mediated production of an authentic major histocompatibility class I-restricted epitope from an intact protein substrate. J Biol Chem 274(31):21963-21972 (Pubitemid 29360034)
32. Maiorano E, Loverro G, Viale G, Giannini T, Napola A, Perlino E (1999) Insulin-like growth factor-I expression in normal and diseased endometrium. Int J Cancer 80(2):188-193 (Pubitemid 29001720)
33. Libermann TA, Zerbini LF (2006) Targeting transcription factors for cancer gene therapy. Curr Gana Ther 1:17-33
34. Pallares J, Martinez-Guitarte JL, Dolcet X, Llober D, Rue M, Palacoos J, Prat J, Matias-Guiu X (2004) Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol 204(5):569-577 (Pubitemid 39585956)
35. van Uden P, Kenneth NS, Rocha S (2008) Regulation of hypoxia-inducible factor-1 alpha by NF-kappaB. Biochem J 412(3):477-484 (Pubitemid 351846413)
36. Xie Y (2010) Structure, assembly and homeostatic regulation of the 26S proteasome. J Mol Cell Biol 2:308-317
37. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G, Ljungberg B (2004) Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 93:297-302 (Pubitemid 38253573)
38. Dolcet X, Llobet D, Encinas M et al (2006) Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 281(31):22118-222130 (Pubitemid 44181916)
39. Perkins ND, Gilmore TD (2006) Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ 5:759-772
40. Sixt SU, Peters J (2010) Extracellular alveolar proteasome. Possible role in lung injury and repair. Am Thor Soc 7:91-96
41. Heubner M, Wimberger P, Dahlmann B et al (2011) The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. Gynecol Oncol 120(2):233-238